Abstract

Among twenty-eight novel compounds (twenty-two 2,3-disubstituted-6-[(substituted-phenoxy)methyl-quinoxalines and six 4-[(2,3-disubstituted-quinoxalin-6-yl methoxylbenzoylglutamates) only thirteen were selected at NO for evaluation of their in vitro anticancer activity. The results have shown that compounds 31,c,b,e and 4b were endowed with significantly high values of percent tumor growth inhibition on several tumor cell lines at 10⁻⁴ M, while compound 3t was characterized by a high selectivity, being still strongly inhibiting on three cell lines at 10⁻5 M. Comparison of the presently observed activity with that of the previously described aza-analogues confirms that the effected isosteric substitution is highly valuable in some cases.

I documenti depositati in UnissResearch sono protetti dalle leggi che regolano il diritto d'autore